68 related articles for article (PubMed ID: 28383673)
1. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Vienot A; Beinse G; Louvet C; de Mestier L; Meurisse A; Fein F; Heyd B; Cleau D; d'Engremont C; Dupont-Gossart AC; Lakkis Z; Tournigand C; Bouché O; Rousseau B; Neuzillet C; Bonnetain F; Borg C; Vernerey D
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383673
[TBL] [Abstract][Full Text] [Related]
2. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Yamaguchi T; Machida N; Morizane C; Kasuga A; Takahashi H; Sudo K; Nishina T; Tobimatsu K; Ishido K; Furuse J; Boku N; Okusaka T
Cancer Sci; 2014 Sep; 105(9):1176-81. PubMed ID: 24975505
[TBL] [Abstract][Full Text] [Related]
3. Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer.
Deng GC; Lv Y; Yan H; Sun DC; Qu TT; Pan YT; Han QL; Dai GH
BMC Cancer; 2021 Nov; 21(1):1227. PubMed ID: 34781928
[TBL] [Abstract][Full Text] [Related]
4. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
Apolo AB; Ostrovnaya I; Halabi S; Iasonos A; Philips GK; Rosenberg JE; Riches J; Small EJ; Milowsky MI; Bajorin DF
J Natl Cancer Inst; 2013 Apr; 105(7):499-503. PubMed ID: 23411591
[TBL] [Abstract][Full Text] [Related]
5. Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes.
O'Reilly EM; Cockrum P; Surinach A; Wu Z; Dillon A; Yu KH
Cancer Med; 2020 Nov; 9(22):8480-8490. PubMed ID: 32997898
[TBL] [Abstract][Full Text] [Related]
6. Duration of therapy for locally advanced pancreatic cancer: Does it matter?
Tuli R; David J; Lobaugh S; Zhang Z; O'Reilly EM
Cancer Med; 2020 Jul; 9(13):4572-4580. PubMed ID: 32368871
[TBL] [Abstract][Full Text] [Related]
7. Prognosticators of survival in patients with metastatic pancreatic cancer and ascites.
Berger JM; Alany A; Berchtold L; Puhr R; Friedrich A; Scheiner B; Prager GW; Preusser M; Berghoff AS; Bergen ES
ESMO Open; 2023 Dec; 8(6):102048. PubMed ID: 37977000
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China.
Han J; Liu J; Yu Z; Huang R; Zhao L; Xu Y; Chen M; He G; Song Q; Li W; Zhang C
BMJ Open; 2023 Jun; 13(6):e069794. PubMed ID: 37349101
[TBL] [Abstract][Full Text] [Related]
9. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative Prediction Model.
Walma M; Maggino L; Smits FJ; Borggreve AS; Daamen LA; Groot VP; Casciani F; de Meijer VE; Wessels FJ; van der Schelling GP; Nieuwenhuijs VB; Bosscha K; van der Harst E; van Dam R; Liem MS; Festen S; Stommel MWJ; Roos D; Wit F; de Hingh IH; Bonsing BA; Busch OR; Groot Koerkamp B; Kazemier G; Besselink MG; Salvia R; Malleo G; Molenaar IQ; van Santvoort HC;
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541904
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment in pancreatic cancer: Evidence-based medicine? A systematic review and meta-analysis.
D'Angelo F; Antolino L; Farcomeni A; Sirimarco D; Kazemi Nava A; De Siena M; Petrucciani N; Nigri G; Valabrega S; Aurello P; Ramacciato G
Med Oncol; 2017 May; 34(5):85. PubMed ID: 28391577
[TBL] [Abstract][Full Text] [Related]
11. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Khorana AA; Mangu PB; Berlin J; Engebretson A; Hong TS; Maitra A; Mohile SG; Mumber M; Schulick R; Shapiro M; Urba S; Zeh HJ; Katz MHG
J Clin Oncol; 2017 Jul; 35(20):2324-2328. PubMed ID: 28398845
[TBL] [Abstract][Full Text] [Related]
12. A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk.
Gomez-Rubio P; Rosato V; Márquez M; Bosetti C; Molina-Montes E; Rava M; Piñero J; Michalski CW; Farré A; Molero X; Löhr M; Ilzarbe L; Perea J; Greenhalf W; O'Rorke M; Tardón A; Gress T; Barberá VM; Crnogorac-Jurcevic T; Muñoz-Bellvís L; Domínguez-Muñoz E; Gutiérrez-Sacristán A; Balsells J; Costello E; Guillén-Ponce C; Huang J; Iglesias M; Kleeff J; Kong B; Mora J; Murray L; O'Driscoll D; Peláez P; Poves I; Lawlor RT; Carrato A; Hidalgo M; Scarpa A; Sharp L; Furlong LI; Real FX; La Vecchia C; Malats N;
Ann Oncol; 2017 Jul; 28(7):1618-1624. PubMed ID: 28383714
[TBL] [Abstract][Full Text] [Related]
13. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients.
Youngwirth LM; Nussbaum DP; Thomas S; Adam MA; Blazer DG; Roman SA; Sosa JA
J Surg Oncol; 2017 Aug; 116(2):127-132. PubMed ID: 28407261
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.
Sohal DP; Mangu PB; Laheru D
J Oncol Pract; 2017 Apr; 13(4):261-264. PubMed ID: 28399388
[No Abstract] [Full Text] [Related]
15. Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Zhang SH; Liu GF; Li XF; Liu L; Yu SN
J Cell Physiol; 2018 Apr; 233(4):3352-3374. PubMed ID: 28926090
[TBL] [Abstract][Full Text] [Related]
16. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Specenier PM; Remenar E; Buter J; Schrijvers DL; Bergamini C; Licitra LF; Awada A; Clement PM; Fortpied C; Menis J; Vermorken JB
Ann Oncol; 2017 Sep; 28(9):2219-2224. PubMed ID: 28911062
[TBL] [Abstract][Full Text] [Related]
17. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
Fernandes GDS; Braghiroli MI; Artioli M; Paterlini ACCR; Teixeira MC; Gumz BP; Girardi DDM; Braghiroli OFM; Costa FP; Hoff PM
J Gastrointest Cancer; 2018 Dec; 49(4):470-475. PubMed ID: 28884286
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
19. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.
Cespedes Feliciano EM; Lee VS; Prado CM; Meyerhardt JA; Alexeeff S; Kroenke CH; Xiao J; Castillo AL; Caan BJ
Cancer; 2017 Dec; 123(24):4868-4877. PubMed ID: 28881381
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
